Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Camp4 Therapeutics Corp

Get SEC filing alerts via email and in your feed for Camp4 Therapeutics Corp

CAMP

Camp4 Therapeutics Corp

About Camp4 Therapeutics Corp

CAMP4 Therapeutics is a biopharmaceutical company developing RNA-based therapeutics to upregulate gene expression and treat genetic diseases. Its proprietary RAP Platform identifies regulatory RNAs to create antisense oligonucleotides that modulate gene activity. Focused on metabolic and neurological disorders, the company aims to deliver targeted, disease-modifying treatments with broad applicability across haploinsufficient and loss-of-function conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Camp4 Therapeutics Corp

1
1
Camp4 Therapeutics Corp CAMP4 Therapeutics Reports Q1 2026 Financial Results with Increased Revenue and Net Loss

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Camp4 Therapeutics Corp Camp4 Therapeutics Reports $80.4 Million Net Loss and Increased Revenue in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Camp4 Therapeutics Corp CAMP4 Therapeutics Reports Q3 2025 Financial Results with Revenue Increase and Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Camp4 Therapeutics Corp CAMP4 Therapeutics Reports $1.5M Revenue in Q2 2025, Faces $12.6M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Camp4 Therapeutics Corp CAMP4 Therapeutics Reports Q1 2025 Financial Results with Modest Revenue Growth

Via official filing (AI summary) | about 1 year ago | 0 comments